ALBO News and Press, Albireo Pharma Inc. From 07/20/21

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by...

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by...

Grandbrothers/iStock Editorial via Getty Images According to the FDA website, the U.S. regulators have approved Bylvay, an oral treatment developed by Albireo Pharma ([[ALBO]] -4.8%) for pediatric cholestatic liver diseases. Bylvay, the company’s lead candidate, had been gran...

Albireo Pharma (ALBO) perks up 2% premarket after announcing European Commission ((EC)) authorization of Bylvay (odevixibat) for the treatment of all subtypes of progressive familial intrahepatic cholestasis ((PFIC)). PFIC is a rare and devastating disorder affecting young children ...

– First approval in the world of Bylvay for the treatment of PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – European Commission (EC) decision based on data from the largest Phase 3 PFIC trial to date – ...

You can read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The earnings season heats up in a big way next week with IBM (NYSE:IBM), Netflix (NASDAQ:NFLX), Chipotle (NYSE:CMG), Coc...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thurs...

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandler’s V...